Key Findings
Sumitomo Pharma has initiated the first patient treatment using a pioneering stem-cell therapy for Parkinson’s disease. The first transplant was conducted in October at Kyoto University Hospital following conditional approval from Japanese regulators in March. The company plans to perform transplants on 20 to 30 patients by March 2029 and is currently conducting a clinical trial in the United States.
Technical Details
The treatment utilizes induced Pluripotent Stem (iPS) cells derived from healthy donors. These cells are induced from mature, specialized cells back to a juvenile state and then developed into precursors of dopamine-producing brain cells, which are absent in Parkinson’s patients. The procedure involves transplanting millions of these iPS cells directly into the patient’s brain.
In a prior clinical trial involving seven patients aged 50 to 69, implants of either five million or 10 million cells were administered to both sides of the brain. Monitoring over a two-year period revealed no major adverse effects, and four of the patients demonstrated symptom improvement.
Background & Context
Parkinson’s disease is a chronic, degenerative neurological disorder affecting the motor system, characterized by shaking and movement difficulties. According to the Parkinson’s Foundation, more than 10 million people worldwide live with the condition. Current therapies are limited to improving symptoms and do not slow or halt the progression of the disease.
Significance & Outlook
The therapy will move toward full approval in Japan if safety and efficacy are confirmed over the next seven years. This development follows a broader trend of iPS cell applications in Japan; a hospital in Osaka recently performed the world’s first surgery using iPS cell sheets of heart muscle to restore heart function and form new blood vessels, a therapy that also received conditional approval in March.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
